TG Therapeutics Inc (TGTX)
Return on total capital
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 375 | 102,725 | 49,235 | 20,633 | -18,944 | -168,691 | -162,958 | -192,838 | -233,723 | -283,888 | -322,439 | -344,769 | -338,604 | -339,198 | -312,551 | -273,594 | -224,773 | -199,912 | -184,611 | -169,055 |
| Long-term debt | US$ in thousands | 244,158 | 102,537 | 101,326 | 100,118 | 98,908 | 97,700 | 96,503 | 71,135 | 71,135 | 68,947 | 67,249 | 66,788 | — | — | — | 7,716 | 15,074 | 22,233 | 29,201 | 28,970 |
| Total stockholders’ equity | US$ in thousands | 192,157 | 177,568 | 160,109 | 160,502 | 164,769 | 40,453 | 27,433 | 58,587 | 100,481 | 129,035 | 170,386 | 237,153 | 311,517 | 383,130 | 445,285 | 519,350 | 170,658 | 194,227 | -1,353 | 38,615 |
| Return on total capital | 0.09% | 36.67% | 18.83% | 7.92% | -7.18% | -122.10% | -131.49% | -148.65% | -136.19% | -143.39% | -135.69% | -113.43% | -108.70% | -88.53% | -70.19% | -51.91% | -121.02% | -92.36% | -662.92% | -250.14% |
September 30, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $375K ÷ ($244,158K + $192,157K)
= 0.09%
The return on total capital for TG Therapeutics Inc has been volatile over the past few quarters, ranging from significantly negative to positive values. The company experienced a steep decline in return on total capital in the second and third quarters of 2023, with values of -122.10% and -131.49% respectively, indicating inefficiency in utilizing its capital resources during that period.
However, there was a notable improvement in the return on total capital in the subsequent quarters, especially in the second quarter of 2024 where it reached 36.67%. This sharp increase suggests that the company may have implemented strategic changes or improved its operational efficiency to generate higher returns on its invested capital.
Overall, the return on total capital for TG Therapeutics Inc has shown a mixed performance, with periods of negative returns followed by significant positive returns. It will be important to monitor future trends in this ratio to assess the company's ability to effectively utilize its capital resources and generate sustainable returns for its shareholders.
Peer comparison
Sep 30, 2024